Compare Citius Pharmaceuticals Inc (CTXR) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ProShares Ultra Gold ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while ProShares Ultra Gold ETF trades at $46.32 (market cap $716.59M). The key difference: ProShares Ultra Gold ETF is far larger — about 52.6× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 2,592,878). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and ProShares Ultra Gold ETF for 23 Days on average.
| CTXR | UGL | |
|---|---|---|
Market Cap | $13.62M | $716.59M |
Volume | 132,438 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $85.62 |
52-Week Low | $0.48 | $42.79 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
UGL shares are trading at $44.43, down 3.29% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $45-$46 with support at $43-$44. Recent market sentiment reflects concerns about gold's performance amid rising Treasury yields and Federal Reserve policy uncertainty, creating headwinds for gold-related equities.
The stock's outlook remains challenged by macroeconomic pressures on gold prices, though potential Fed policy shifts could provide catalysts. Key risks include persistent high yields and dollar strength, while opportunities exist if inflation concerns reignite safe-haven demand. Investors should monitor Fed guidance and gold price trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
